Should I buy Open Orphan shares ahead of the planned demerger?

The Open Orphan share price is up nearly 430% for the year and the company is now planning to spin off non-core assets. Here’s why I won’t be buying new shares just yet.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I bought shares in Open Orphan (LSE:ORPH) in my Stocks and Shares ISA when it traded as Venn Life Sciences. Venn was once a stand-alone integrated drug development consultancy. But it was struggling to attract customers. A strategic collaboration with then stand-alone Open Orphan, which focused on rare and orphan drugs, in 2018 made sense. Orphan drugs are for conditions that are so rare that it is often not profitable to develop them without assistance, typically government financing and outsourcing to service companies like Venn.

In 2019, Open Orphan bought Venn. Then Open Orphan completed a reverse takeover of hVIVO, a pioneer in viral challenge studies. These types of studies can help accelerate the development of drug and vaccines for respiratory and infectious diseases. Open Orphan now provided, in the words of its CEO:

…early clinical development services, clinical trial delivery expertise and virology-related challenge studies, with a particular focus on rare and emerging diseases…our 24-bed quarantine facilities in the UK are best in class for vaccine and virus-related development…

The reverse takeover of hVIVO completed in January 2020, about the same time as the coronavirus pandemic started to sweep across the world.

Covid-19 impact

It was, for want of a better word, luck that Open Orphan had a unique set of services that suddenly saw increased demand as the pandemic broke. But, Open Orphan’s management did seize the opportunity. A slew of work on not just Covid-19 but other respiratory infections has come Open Orphan’s way in 2020 and into 2021. In the last quarter of 2020, the company became operationally profitable.

Over the last year, the Open Orphan share price has rocketed by 429%. As an Open Orphan shareholder, I am delighted. But, I am not going to cash in just yet. I think there are further price rises to come. The Covid-19 pandemic has woken the world up to the threat of emerging viral diseases and the burden of existing ones. The study and production of vaccines and treatments for these types of diseases will continue indefinitely.

Open Orphan is now focused on testing vaccines and antivirals using human challenge study clinical trials. It has built expertise and reputation in this area that it can leverage in the future. Its facilities are booked until the end of 2021, and its new patented data platform of various biomarkers might be of interest to big tech, wearables, and traditional biopharma industry companies.

Open Orphan demerger

Open Orphan is a life science service company. It has acquired, through the hVIVO deal, wholly-owned intellectual property for developmental treatments. Open Orphan is planning to spin off these developmental assets into a separate company. The company will retain equity stakes in two developmental businesses. As a shareholder, I will vote in favour of the move in the general meeting on 29 April 2021.

Buying shares in Open Orphan gives a slice of ownership of a life science service company focused on vaccine and treatment development of viral respiratory illnesses with operations spread across the UK, France and the Netherlands

Source: company presentation

If the motion is passed at the general meeting, and I think it will be, I will end up with two sets of shares. I want the Open Orphan shares, but I don’t want the shares in the developmental asset company. It looks like I will have to wait for up to nine months before I can sell those unwanted shares. Therefore, I will not be buying any more Open Orphan shares before the planned demerger. But, after it completes, I will.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie owns shares of Open Orphan plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Down 5%, Glencore’s share price looks a serious bargain to me now

Glencore’s share price looks undervalued to me, supported by strong earnings growth prospects and the potential resumption of extra shareholder…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

I’d invest £6,580 in this FTSE 250 REIT for £500 passive income

This FTSE 250 renewable energy enterprise is on track to become a Dividend Aristocrat! Here’s how I’d invest to earn…

Read more »

Investing Articles

Buying 1,000 of some dividend shares today unlocks £45 in weekly passive income!

These shares are among the biggest dividend payers in the FTSE 100. Should investors be buying them now to earn…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

If I’d put £5k in index funds 5 years ago, here’s what I’d have now

Investing in index funds is an excellent way to grow wealth with minimal effort. But how much money can investors…

Read more »

Investing Articles

10.2% yield! 1 of the top income stocks to buy in July?

A 10% yield's pretty rare, but this firm's been growing shareholder payouts for nine years! Does that make it one…

Read more »

Investing Articles

‘FTSE 100 to skyrocket to 10,000’! 1 cheap stock I’d buy before the surge

Analyst forecasts predict a massive surge for the FTSE 100 may be coming by April 2025! Should investors snap up…

Read more »

Investing Articles

My Taylor Wimpey share price prediction for the second half of 2024

Having underperformed the FTSE 100 from January to June, our writer reckons the Taylor Wimpey share price might enjoy a…

Read more »

Investing Articles

£10k in savings? Here’s how I’d aim to turn it into a £4,894 annual passive income with Aviva shares

Aviva might be one of the FTSE 100's hottest dividend shares right now. I'm banking on it to provide me…

Read more »